Brief: Rvl Pharmaceuticals PLC Announces Preliminary Second Quarter 2022 Upneeq® Net Product Sales Results
07/07/2022 20:49
July 7 (Reuters) - RVL Pharmaceuticals PLC RVLP.O :
* RVL PHARMACEUTICALS PLC ANNOUNCES PRELIMINARY SECOND
QUARTER
2022 UPNEEQ® NET PRODUCT SALES RESULTS
* RVL PHARMACEUTICALS PLC - REAFFIRMS Q4 2022 UPNEEQ NET
PRODUCT
SALES GUIDANCE OF $20 TO $25 MILLION
* RVL PHARMACEUTICALS PLC - EXPECTS Q2 2022 PRELIMINARY
UPNEEQ NET
PRODUCT SALES OF APPROXIMATELY $8.4 MILLION
* RVL PHARMACEUTICALS PLC - EXPECTS APPROXIMATELY 2,200
CUMULATIVE
UNIQUE MEDICAL AESTHETICS PRACTICES PLACED ORDERS FOR UPNEEQ
THROUGH QUARTER-END
Source text for Eikon: ID:nPnbGwBkWa
Further company coverage: RVLP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RVL Pharmaceuticals
See all newsBrief: RVL Pharmaceuticals Says High Court Of Ireland Made A Winding Up Order In Respect Of Co On Feb 12
Brief: RVL Pharmaceuticals Says Co Issued Petition In Central Office Of High Court In Ireland To Wind Up Company
Brief: RVL Completes Financial Restructuring
Brief: Rvl Pharmaceuticals PLC Received Delisting Notice From Listing Qualifications Department Of Nasdaq Stock Market Llc
U.S. STOCKS ON THE MOVE-Cerevel Therapeutics, Scholar Rock, Helius